Vitamin K: Metabolism, physiopathology, implication in the inter- and intra-individual variability in the response to the vitamin K antagonists;Vitamine K: Métabolisme, éléments de physiopathologie, implication dans la variabilité inter- et intra-individuelle de la réponse au traitement par les antivitamines K

Hematologie

Volumn 12, Issue 6, 2006, Pages 389-399

  Siguret, Virginie ^a,b  

^a HÔPITAL CHARLES FOIX   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Antivitamin K; CYP2C9; Vitamin K; Vitamin K dependant protein; VKOR

Indexed keywords

ALPHA GLUTAMYL CARBOXYLASE; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; CARBOXYLASE; CYTOCHROME P450 2C9; FATTY ACID BINDING PROTEIN; GLUTAMIC ACID; GROWTH ARREST SPECIFIC PROTEIN 6; HYDROQUINONE; MATRIX GIA PROTEIN; MATRIX PROTEIN; MENADIONE EPOXIDE; OSTEOCALCIN; OXIDOREDUCTASE; PROTEIN C; PROTEIN S; PROTHROMBIN; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE; VITAMIN K GROUP; WARFARIN;

ACUTE DISEASE; BONE METABOLISM; DIETARY INTAKE; GENETIC POLYMORPHISM; HAPLOTYPE; HEMOSTASIS; HUMAN; OSTEOPOROSIS; PATHOPHYSIOLOGY; PROTEIN DEGRADATION; PROTEIN FUNCTION; REVIEW; VITAMIN INTAKE; VITAMIN METABOLISM;

EID: 33847770723     PISSN: 12647527     EISSN: None     Source Type: Journal    
DOI: 10.1684/hma.2006.0081     Document Type: Review

References (40)

1. Dam H. The antihaemorrhagic vitamin of the chick. Biochem J 1935 ; 29 : 1273-85.
2. Stafford DW. The vitamin K cycle. J Thromb Haemost 2005 ; 3 : 1873-8.
3. Plaza SM, Lamson DW. Vitamin K2 in bone metabolism and osteoporosis. Altern Med Rev 2005 ; 10 : 24-35.
4. Berkner KL, Runge KW. The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis. J Thromb Haemost 2004 ; 2 : 2118-32.
5. Khan T, Wynne H, Wood P, Torrance A, Hankey C, Avery P, Kesteven P, Kamali F. Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin. Br J Haematol 2004 ; 124 : 348-54.
6. Wallin R, Martin LF. Warfarin poisoning and vitamin K antagonism in rat and human liver. Design of a system in vitro that mimics the situation in vivo. Biochem J 1987 ; 241 : 389-96.
7. Wallin R, Hutson SM. Warfarin and the vitamin K-dependent γ-carboxylation system. Trends Mol Med 2004 ; 10 : 299-302.
8. Vermeer C, Schurgers LJ. A comprehensive review of vitamin K and vitamin K antagonists. Hematol Oncol Clin North Am 2000 ; 14 : 339-53.
9. Berkner KL. The vitamin K-dependent carboxylase. Annu Rev Nutr 2005 ; 25 : 127-49.
10. Soute BAM, Jin DY, Spronk HMH, Mutucumarana VP, Lin PJ, Hackeng TM, Stafford DW, Vermeer C. Characteristics of recombinant W501S mutated human γ-glutamyl carboxylase. J Thromb Haemost 2004 ; 2 : 597-604.
11. Rost S, Fregin A, Koch D, Compes M, Müller CR, Oldenburg J. Compound heterozygous mutations in the γ-glutamyl carboxylase gene cause combined deficiency of all vitamin K-dependent blood coagulation factors. Br J Haematol 2004 ; 126 : 546-9.
12. Darghouth D, Hallgren K, Shtofman R, Mrad A, Gharbi Y, Maherzi A, Kastally R, LeRicousse S, Berkner K, Rosa JP. Compound heterozygosity of novel missense mutations in the γ-carboxylase gene causes hereditary combined vitamin K-dependent coagulation factor deficiency. Blood 2006 ; (e-pub).
13. Camire RM, Larson PJ, Stafford DW, High KA. Enhanced γ- carboxylation of recombinant factor X using a chimeric construct containing the prothrombin propeptide. Biochemistry 2000 ; 39 : 14322-9.
14. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hortnagel K, Pelz HJ, Lappegard K, Seifried E, Scharrer I, Tuddenham EG, Muller CR, Strom TM, Oldenburg J. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004 ; 427 : 537-41.
15. Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW. Identification of the gene for vitamin K epoxide reductase. Nature 2004 ; 427 : 541-4.
16. Bodin L, Horellou MH, Flaujac C, Loriot MA, Samama MM. A vitamin K epoxide reductase comples subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistance. J Thromb Haemost 2005 ; 3 : 1533-5.
17. Fasco MJ, Principe LM, Walsh WA, Friedman PA. Warfarin inhibition of vitamin K 2,3 epoxide reductase in rat liver microsomes. Biochemistry 1983 ; 22 : 5655-60.
18. Murshed M, Schinke T, McKee MD, Karsenty G. Extracellular matrix mineralization is regulated locally : different roles of the two Gla-containing proteins. J Cell Biol 2004 ; 165 : 625-30.
19. Cashman KD. Vitamin K status may be an important determinant of childhood bone health. Nutr Rev 2005 ; 63 : 284-9.
20. Wang Y, Zhang W, Zhang Y, Yang Y, Sun L, Hu S, Chen J, Zhang C, Zheng Y, Zhen Y, Sun K, Fu C, Yang T, Wang J, Sun J, Wu H, Glasgow W, Hui R. VKORC1 haplotypes are associated with arterial vascular diseases (stroke, coronary heart disease and aortic dissection). Circulation 2006 ; 113 : 1615-21.
21. Koos R, Mahnken AH, Mühlenbruch G, Brandenburg V, Pflueger B, Wildberger JE, Kühl HP. Relation of oral anticoagulation to cardiac valvular and coronary calcium assessed by multislice spiral computed tomography. Am J Cardiol 2005 ; 96 : 747-9.
22. Schurgers LJ, Teunissen KJF, Knapen MHJ, Kwaijtaal M, van Diest R, Appels A, Reutelingsperger CP, Cleutjens JPM, Vermeer C. Novel conformation-specific antibodies against matrix γ-carboxyglutamic acid (Gla) protein. Arterioscler Thromb Vasc Biol 2005 ; 25 : 1629-33.
23. Penning-van Beest FJ, van Meegen E, Rosendaal FR, Stricker BH. Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation. Thromb Haemost 2001 ; 86 : 569-74.
24. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 2004 ; 91 : 87-94.
25. Franco V, Polanczyk CA, Clausell N, Rohde LE. Role of dietary vitamin K intake in chronic oral anticoagulation : prospective evidence from observational and randomized protocols. Am J Med 2004 ; 116 : 651-6.
26. Visser LE, Penning-van Beest FJ, Kasbergen AA, De Smet PA, Vulto AG, Hofman A, Stricker BH. Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants. Thromb Haemost 2002 ; 88 : 705-10.
27. Kirchheiner J, Brockmöller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005 ; 77 : 1-16.
28. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999 ; 353 : 717-9.
29. Margaglione M, Colaizzo D, D'Andrea G, Brancaccio V, Ciampa A, Grandone E, Di Minno G. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 2000 ; 84 : 775-8.
30. Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000 ; 96 : 1816-9.
31. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002 ; 287 : 1690-8.
32. Kamali F, Khan TI, King BP, Frearson R, Kesteven P, Wood P, Daly AK, Wynne H. Contribution of agen body size and CYP2C9 genotype to anticoagulant. Clin Pharmacol Ther 2004 ; 75 : 204-12.
33. Siguret V, Gouin I, Golmard JL, Geoffroy S, Andreux JP, Pautas E. Polymorphismes du cytochrome P450 2C9 (CYP2C9) et posologie à l'équilibre pour des patients âgés traités par warfarine. Rev Med Interne 2004 ; 25 : 271-4.
34. Visser LE, van Schaik RH, van Vliet M, Trienekens PH, De Smet PA, Vulto AG, Hofman A, van Duijn CM, Stricker BH. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Thromb Haemost 2004 ; 92 : 61-6.
35. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, Grandone E, Margaglione M. A polymorphism in VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005 ; 105 : 645-9.
36. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Bough DK, Thummel KE, Veenstra DL, Rettie AE. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005 ; 352 : 2285-93.
37. Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C, Jaillon P, Beaune P, Laurent-Puig P, Becquemont L, Loriot MA. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005 ; 106 : 135-40.
38. Veenstra DL, You JHS, Rieder MJ, Farin FM, Wilkerson HW, Blough DK, Cheng G, Rettie A. Association of vitamin K episode reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet Genom 2005 ; 15 : 687-91.
39. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements : proposal for a new dosing regimen. Blood 2005 ; 106 : 2329-33.
40. Siguret V, Gouin I, Debray M, Perret-Guillaume C, Boddaert J, Mahé I, Donval V, Seux M, Romain-Pilotaz M, Gisselbrecht M, Verny M, Pautas E. Initiation of warfarin therapy in elderly medical inpatients : a safe and accurate regimen. Am J Med 2005 ; 118 : 137-42.